Loading...
•
Jun 30, 2021
Zimmer Biomet Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021.
Key Takeaways
Zimmer Biomet's second quarter net sales were $2.027 billion, an increase of 65.3% over the prior year period, and an increase of 60.7% on a constant currency basis. Second quarter 2021 net sales increased 1.9% when compared to the pre-pandemic second quarter 2019, and were flat on a constant currency basis. Net earnings for the second quarter of 2021 were $141.9 million, or $400.5 million on an adjusted basis. Diluted earnings per share were $0.67 for the second quarter and adjusted diluted earnings per share were $1.90.
Second quarter net sales of $2.027 billion increased 65.3%, 60.7% on a constant currency basis
Second quarter net sales of $2.027 billion increased 65.3%, 60.7% on a constant currency basis
Second quarter diluted earnings per share were $0.67; adjusted diluted earnings per share were $1.90
Company updates 2021 financial guidance, narrowing range for full year outlook
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is updating its full-year 2021 financial guidance to narrow its previous projected ranges for revenue growth and adjusted diluted EPS:
Positive Outlook
- 2021 reported revenue growth: 14.5% - 16.5%.
- Foreign Currency Exchange Impact: 1.5%
- Adjusted Operating Profit Margin: 26.5% - 27.0%
- Adjusted Tax Rate: 16.0% - 16.5%
- Adjusted Diluted EPS: $7.65 - $7.95
Revenue & Expenses
Visualization of income flow from segment revenue to net income